Previous 10 | Next 10 |
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therap...
2023-05-18 08:56:42 ET Legend Biotech press release ( NASDAQ: LEGN ): Q1 GAAP EPS of -$0.34. Revenue of $36.3M (-27.4% Y/Y). For further details see: Legend Biotech GAAP EPS of -$0.34, revenue of $36.3M
New and updated data from the CARTITUDE Clinical Development Program and LEGEND-2 study evaluating ciltacabtagene autoleucel (cilta-cel) will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association’s (EHA) 2023 Hybrid Con...
Eight presentations at ASCO and EHA 2023 Annual Meetings showcase continued leadership in CAR-T cell therapy research for patients with multiple myeloma across various clinical settings First analysis from the CARTITUDE-4 Phase 3 study in relapsed and lenalidomide-refractory multiple myel...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will participate in the 2023 RBC Capital Markets Global Healthcare Conference in New York...
2023-05-08 08:58:46 ET Legend Biotech ( NASDAQ: LEGN ) on Monday priced the registered direct offering of its American Depository Shares to raise about $350 million. The company will sell 5,468,750 ADSs, each representing two ordinary shares, at $64.00 per ADS....
Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it has agreed to sell 5,468,750 American Depositary Shares (“ADS...
2023-05-01 09:25:00 ET With its shares up by 49% in one month and 80% in one year, shareholders of Legend Biotech (NASDAQ: LEGN) are bound to be feeling pretty smart right about now. After commercializing an oncology medicine last year and seeing its stock skyrocket after a very pos...
2023-04-29 04:20:36 ET Summary Demographic trends are powerful and experience little impact from economic cycles. As the Millennial generation enters middle age and surpasses the number of Baby Boomers, the demand for medical screening and testing will increase. Exact Sciences...
2023-04-21 13:09:23 ET Legend Biotech ( NASDAQ: LEGN ) is up ~10% in Friday afternoon trading after releasing abstracts, the results of which were leaked on Tuesday, on its CAR-T therapy Carvykti (ciltacabtagene autoleucel). The results were accidentally released ...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...